SynthesisNeurocritical care2026
Stereotactic Drainage Treatment is Associated with Improved Long-Term Neurological Recovery in Small-to-Moderate Volume Basal Ganglia Hemorrhages: A Systematic Review and Meta-Analysis.
Synthesis in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe optimal management of small-to-moderate volume (≤ 50 mL) basal ganglia spontaneous intracerebral hemorrhage (ICH) is controversial. This meta-analysis aimed to compare the efficacy and safety of stereotactic drainage treatment (SDT) with conservative medical treatment (CMT) in this patient population.
methodsWe queried major databases up to October 2025 for studies comparing SDT versus CMT for basal ganglia ICH ≤ 50 mL. The primary endpoint was good functional recovery (modified Rankin Scale score 0-2). Subgroup analyses were performed on the basis of cohort-mean hematoma volume (< 25 mL vs. 25-50 mL) and follow-up duration.
resultsEleven studies involving 1634 participants were analyzed. Compared with CMT, SDT was associated with a higher proportion of favorable functional outcome up to 12 months (P < 0.001). Subgroup analysis showed consistent functional benefits across both volume strata (< 25 mL and 25-50 mL), with significant superiority emerging from 3 months onwards (all P < 0.001). Mortality did not differ significantly between groups (P = 0.05). SDT also accelerated hematoma resolution and reduced hospital stay (all P < 0.05) without increasing infection (P = 0.17) or rebleeding risks (P = 0.19).
conclusionsSDT was associated with improved long-term functional recovery compared with CMT in cohorts with small-to-moderate basal ganglia ICH. Safety outcomes showed no statistically significant differences between groups. Large, multicenter randomized trials with standardized protocols are needed to confirm SDT's efficacy and safety and to refine patient selection.
Indexed as
Identifiers
42010003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.